Payment overview · 2025
General Payments
$686.38
40 reported records · 7 companies
Healthcare provider profile · identity verified
Michael C Ong, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VANDERGRIFT, PA · NPI 1639162969
Verified facts
What the public records show
CMS Open Payments records show Michael C Ong, MD received $686.38 in general payments during 2025 across 40 reported records.
GlaxoSmithKline, LLC. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Prolia, Relistor, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Relistor by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $271.33 | 39.5% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $189.36 | 27.6% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $141.42 | 20.6% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.06 | 5.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.22 | 3.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.73 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.26 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $666.16 | 39 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $271.33 | 17 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $167.60 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $166.92 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $72.79 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $72.79 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.63 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.63 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 234 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 23 | exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 161 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 17 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
161 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 932 | 287 |
| Atorvastatin Calcium | Atorvastatin Calcium | 865 | 295 |
| Levothyroxine Sodium | Levothyroxine Sodium | 616 | 184 |
| Pantoprazole Sodium | Pantoprazole Sodium | 608 | 204 |
| Metoprolol Succinate | Metoprolol Succinate | 573 | 172 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 481 | 178 |
| Losartan Potassium | Losartan Potassium | 480 | 157 |
| Gabapentin | Gabapentin | 425 | 122 |
| Lisinopril | Lisinopril | 397 | 131 |
| Metoprolol Tartrate | Metoprolol Tartrate | 388 | 116 |
| Omeprazole | Omeprazole | 368 | 116 |
| Metformin Hcl | Metformin Hcl | 332 | 123 |
| Simvastatin | Simvastatin | 276 | 91 |
| Furosemide | Furosemide | 275 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 245 | 76 |
| Eliquis | Apixaban | 234 | 61 |
| Famotidine | Famotidine | 224 | 66 |
| Meloxicam | Meloxicam | 219 | 85 |
| Sertraline Hcl | Sertraline Hcl | 219 | 67 |
| Valsartan | Valsartan | 218 | 78 |
| Allopurinol | Allopurinol | 188 | 58 |
| Trazodone Hcl | Trazodone Hcl | 186 | 53 |
| Ezetimibe | Ezetimibe | 182 | 59 |
| Potassium Chloride | Potassium Chloride | 172 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 169 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 52 |
| Montelukast Sodium | Montelukast Sodium | 163 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 161 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 65 |
| Glipizide Er | Glipizide | 149 | 37 |
| Ozempic | Semaglutide | 149 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 54 |
| Metformin Hcl Er | Metformin Hcl | 134 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 40 |
| Labetalol Hcl | Labetalol Hcl | 126 | 34 |
| Alendronate Sodium | Alendronate Sodium | 123 | 42 |
| Glimepiride | Glimepiride | 122 | 28 |
| Finasteride | Finasteride | 121 | 43 |
| Xarelto | Rivaroxaban | 114 | 24 |
| Azelastine Hcl | Azelastine Hcl | 108 | 45 |
| Azithromycin | Azithromycin | 108 | 87 |
| Methylprednisolone | Methylprednisolone | 108 | 84 |
| Donepezil Hcl | Donepezil Hcl | 103 | 23 |
| Jardiance | Empagliflozin | 101 | 26 |
| Mounjaro | Tirzepatide | 99 | 18 |
| Prednisone | Prednisone | 98 | 76 |
| Alprazolam | Alprazolam | 97 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 30 |
| Carvedilol | Carvedilol | 93 | 28 |
| Warfarin Sodium | Warfarin Sodium | 89 | 20 |
| Trulicity | Dulaglutide | 82 | 16 |
| Celecoxib | Celecoxib | 77 | 27 |
| Clonazepam | Clonazepam | 77 | 16 |
| Irbesartan | Irbesartan | 76 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 16 |
| Buspirone Hcl | Buspirone Hcl | 73 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 24 |
| Synthroid | Levothyroxine Sodium | 72 | 25 |
| Tramadol Hcl | Tramadol Hcl | 72 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 71 | 15 |
| Atenolol | Atenolol | 63 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 23 |
| Cephalexin | Cephalexin | 60 | 46 |
| Ibuprofen | Ibuprofen | 58 | 34 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 57 | 14 |
| Myrbetriq | Mirabegron | 56 | 14 |
| Pregabalin | Pregabalin | 56 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 20 |
| Glipizide | Glipizide | 52 | 17 |
| Spironolactone | Spironolactone | 52 | 20 |
| Topiramate | Topiramate | 52 | 15 |
| Meclizine Hcl | Meclizine Hcl | 51 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 36 |
| Glyxambi | Empagliflozin/Linagliptin | 48 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 41 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Tradjenta | Linagliptin | 42 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 17 |
| Ramipril | Ramipril | 41 | 14 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 14 |
| Sucralfate | Sucralfate | 39 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 33 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 21 |
| Farxiga | Dapagliflozin Propanediol | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Mirtazapine | Mirtazapine | 35 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Ibu | Ibuprofen | 32 | 20 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 11 |
| Lorazepam | Lorazepam | 31 | 23 |
| Nitroglycerin | Nitroglycerin | 31 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Lactulose | Lactulose | 27 | 18 |
| Linzess | Linaclotide | 27 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Prolia | Denosumab | 23 | 17 |
| Rybelsus | Semaglutide | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Temazepam | Temazepam | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 13 |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Silodosin | Silodosin | 17 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Repaglinide | Repaglinide | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Relistor | Methylnaltrexone Bromide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $686.38 · 40 records | GlaxoSmithKline, LLC. | ABRYSVO, CAMZYOS, COMIRNATY, ELIQUIS, EVENITY, Kerendia, NURTEC ODT, OTEZLA, PREVNAR 20, PROLIA, RELISTOR, REPATHA, TRELEGY ELLIPTA, ZAVZPRET, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error